These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 30558663)

  • 21. Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer.
    Banville AC; Wouters MCA; Oberg AL; Goergen KM; Maurer MJ; Milne K; Ashkani J; Field E; Ghesquiere C; Jones SJM; Block MS; Nelson BH
    Gynecol Oncol; 2021 Feb; 160(2):520-529. PubMed ID: 33342620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors.
    Tomar S; Zhang J; Khanal M; Hong J; Venugopalan A; Jiang Q; Sengupta M; Miettinen M; Li N; Pastan I; Ho M; Hassan R
    Mol Cancer Ther; 2022 Jul; 21(7):1195-1206. PubMed ID: 35499461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induced expression of CCL19 promotes the anti-tumor ability of CAR-T cells by increasing their infiltration ability.
    Hu JF; Wang ZW; Liao CY; Chen ZW; Kang FP; Lin CF; Lin TS; Huang L; Tian YF; Chen S
    Front Immunol; 2022; 13():958960. PubMed ID: 35990619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer.
    Lv J; Zhao R; Wu D; Zheng D; Wu Z; Shi J; Wei X; Wu Q; Long Y; Lin S; Wang S; Wang Z; Li Y; Chen Y; He Q; Chen S; Yao H; Liu Z; Tang Z; Yao Y; Pei D; Liu P; Zhang X; Zhang Z; Cui S; Chen R; Li P
    J Hematol Oncol; 2019 Feb; 12(1):18. PubMed ID: 30777106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of fludarabine and treosulfan on ovarian tumor cells and mesothelin chimeric antigen receptor T cells.
    El-Serafi I; Micallef Nilsson I; Moter A; Duan Z; Mattsson J; Magalhaes I
    Cancer Immunol Immunother; 2024 Jul; 73(9):163. PubMed ID: 38954005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases.
    Riese MJ; Wang LC; Moon EK; Joshi RP; Ranganathan A; June CH; Koretzky GA; Albelda SM
    Cancer Res; 2013 Jun; 73(12):3566-77. PubMed ID: 23576561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer.
    Zhu Y; Zuo D; Wang K; Lan S; He H; Chen L; Chen X; Feng M
    J Cancer Res Clin Oncol; 2023 Nov; 149(16):15027-15038. PubMed ID: 37612388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
    Mehta RS; Rezvani K
    Front Immunol; 2018; 9():283. PubMed ID: 29497427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
    Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
    Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Invariant NKT cells suppress CD8(+) T-cell-mediated allergic contact dermatitis independently of regulatory CD4(+) T cells.
    Goubier A; Vocanson M; Macari C; Poyet G; Herbelin A; Nicolas JF; Dubois B; Kaiserlian D
    J Invest Dermatol; 2013 Apr; 133(4):980-7. PubMed ID: 23190881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells.
    Shiozawa M; Chang CH; Huang YC; Chen YC; Chi MS; Hao HC; Chang YC; Takeda S; Chi KH; Wang YS
    BMC Immunol; 2018 Aug; 19(1):27. PubMed ID: 30075754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breaking through the treatment desert of conventional mesothelin-targeted CAR-T cell therapy for malignant mesothelioma: A glimpse into the future.
    Wang Y; Zhao G; Xing S; Wang S; Li N
    Pharmacol Res; 2024 Jun; 204():107220. PubMed ID: 38768670
    [No Abstract]   [Full Text] [Related]  

  • 33. Mesothelin, a novel immunotherapy target for triple negative breast cancer.
    Tchou J; Wang LC; Selven B; Zhang H; Conejo-Garcia J; Borghaei H; Kalos M; Vondeheide RH; Albelda SM; June CH; Zhang PJ
    Breast Cancer Res Treat; 2012 Jun; 133(2):799-804. PubMed ID: 22418702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers.
    O'Hara MH; Stashwick C; Plesa G; Tanyi JL
    Immunotherapy; 2017 Aug; 9(9):767-780. PubMed ID: 28771103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer.
    Kim M; Pyo S; Kang CH; Lee CO; Lee HK; Choi SU; Park CH
    PLoS One; 2018; 13(6):e0198347. PubMed ID: 29874279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Control of human mesothelin-expressing tumors by DNA vaccines.
    Chang CL; Wu TC; Hung CF
    Gene Ther; 2007 Aug; 14(16):1189-98. PubMed ID: 17581599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Invariant NKT cells are expanded in peripheral blood but are undetectable in salivary glands of patients with primary Sjögren's syndrome.
    Guggino G; Ciccia F; Raimondo S; Giardina G; Alessandro R; Dieli F; Sireci G; Triolo G
    Clin Exp Rheumatol; 2016; 34(1):25-31. PubMed ID: 26633038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.
    Yong CS; John LB; Devaud C; Prince MH; Johnstone RW; Trapani JA; Darcy PK; Kershaw MH
    Oncotarget; 2016 Jun; 7(23):34582-98. PubMed ID: 27153556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Specific cytotoxicity of a novel HER2-based chimeric antigen receptor modified T lymphocytes against HER2-positive tumor cells].
    Tang HJ; Liu YQ; Bian XC; Feng HL; Gu B; Sun H; Zuo CX; Zhou FY; Liu J
    Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):714-720. PubMed ID: 29050075
    [No Abstract]   [Full Text] [Related]  

  • 40. Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells.
    Hung CF; Tsai YC; He L; Wu TC
    Gene Ther; 2007 Jun; 14(12):921-9. PubMed ID: 17377599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.